Russian pharmaceutical company Polysan plans to infuse approximately 4 billion roubles ($60 million) in the localization of full-cycle production of a drug from German peer Bayer.
As part of the preparations, the production of the anticoagulant drug Xarelto, rivaroxaban, will be established at the facilities of Polysan.
In the preparations, part of the future production at the plant will be supplied for exports. Furthermore, Polysan also plans to increase the production of its own antiviral drug Cytoflavin.
The implementation of the scheme will be part of a large-scale investment program, which has been carried out by Polysan since 2006, which includes a massive extension of the capacities of its St Petersburg plant.